Skip to main content

Advertisement

Log in

High Prevalence of Latent Tuberculosis Infection in Patients in End-Stage Renal Disease on Hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and Tuberculin Skin Test

  • Clinical and Epidemiological Study
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Background:

Individuals with end-stage renal disease (ESRD) are 10- to 25-fold more likely than immunocompetent people to develop active tuberculosis (TB) and are candidates for being treated for latent TB infection (LTBI). However, diagnosis using the tuberculin skin test (TST) is doubly difficult due to cutaneous anergy and cross-reactions with Bacille–Calmette–Guérin (BCG) vaccination.

Materials and Methods:

This was a prospective, doublematched, cohort study in which 32 ESRD patients and 32 age-matched, healthy controls were enrolled. The TST and two new interferon-γ blood tests, QuantiFERON-TB Gold (QFT-G) and T-SPOT.TB (ELISPOT), were performed. The subjects were followed up 2 years for active TB disease. ELISPOT was done in ESRD patients only.

Results:

Compared to the healthy controls, a high prevalence of LTBI was found in the ESRD patients by TST (62.5%, 95% confidence interval [CI] 43.7–78.9), QFT-G (40.0%, 95% CI 22.7–59.4), and ELISPOT (46.9%, 95% CI 29.1–65.3). Agreement was moderate (kappa [κ] = 0.53) for QFT-G and ELISPOT but only slight between TST and QFT-G (κ = 0.25) and fair between TST and ELISPOT (κ = 0.32). ESRD (p = 0.03) and diabetes mellitus (p = 0.04) were significant risk factors for QFT-G positivity on the multivariable analysis. The overall rate of active TB was 1.66 cases per 100 person-years (pys), with the rate higher in patients with ESRD (3.53 per 100 pys) and those with positive (3.40 per 100 pys) and indeterminate QFT results (30.16 per 100 pys), although the difference was not statistically significant. Sensitivity, specificity, and positive and negative predictive values of QFT-G for active TB was 100%, 62.1%, 8.3% and 100%.

Conclusion:

This pilot study is the first to compare QFT-G, ELISPOT, and TST in ESRD patients on hemodialysis and demonstrates a high prevalence of LTBI in this population. In our study, the QFT-G was the more accurate method for identifying those truly infected with Mycobacterium tuberculosis, even in BCG-vaccinated individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO. 2007 WHO Fact Sheet. Available at: http://www.who.int/tb/publications/2007/factsheet_2007.pdf. Accessed 15 July 2007.

  2. CDC Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221–S247.

  3. Smirnoff M, Patt C, Seckler B, Adler JJ: Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113: 25–27.

    Article  PubMed  CAS  Google Scholar 

  4. Lundin AP, Adler AJ, Berlyne GM, Friedman EA: Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979; 67: 597–602.

    Article  PubMed  CAS  Google Scholar 

  5. Chia S, Karim M, Elwood RK, FitzGerald JM: Risk of tuberculosis in dialysis patients: a population-based study. Int J Tuberc Lung Dis 1998; 2: 989–991.

    PubMed  CAS  Google Scholar 

  6. Sester U, Junker H, Hodapp T, Schutz A, Thiele B, Meyerhans A, Kohler H, Sester M: Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 2006; 21: 3258–3268.

    Article  PubMed  CAS  Google Scholar 

  7. Fang HC, Lee PT, Chen CL, Wu MJ, Chou KJ, Chung HM: Tuberculosis in patients with end-stage renal disease. Int J Tuberc Lung Dis 2004; 8: 92–97.

    PubMed  CAS  Google Scholar 

  8. Yanai M, Uehara Y, Takeuchi M, Nagura Y, Hoshino T, Hayashi K, Kumasaka K: Evaluation of serological diagnosis tests for tuberculosis in hemodialysis patients. Ther Apher Dial 2006; 10: 278–281.

    Article  PubMed  Google Scholar 

  9. Venkata RK, Kumar S, Krishna RP, Kumar SB, Padmanabhan S, Kumar S: Tuberculosis in chronic kidney disease. Clin Nephrol 2007; 67: 217–220.

    PubMed  CAS  Google Scholar 

  10. Dervisoglu E, Yilmaz A, Sengul E: The spectrum of tuberculosis in dialysis patients. Scand J Infect Dis 2006; 38: 1040–1044.

    Article  PubMed  Google Scholar 

  11. Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM: Tuberculosis in maintenance dialysis patients. Nephron 2001; 88: 138–143.

    Article  PubMed  CAS  Google Scholar 

  12. Klote MM, Agodoa LY, Abbott KC: Risk factors for Mycobacterium tuberculosis in US chronic dialysis patients. Nephrol Dial Transplant 2006; 21: 3287–3292.

    Article  PubMed  Google Scholar 

  13. Centers for Disease Control and Prevention (CDC): Tuberculosis transmission in a renal dialysis center — Nevada, 2003. MMWR Morb Mortal Wkly Rep 2004; 53: 873–875.

    Google Scholar 

  14. Lee E, Holzman RS: Evolution and current use of the tuberculin test. Clin Infect Dis 2002; 34: 365–370.

    Article  PubMed  Google Scholar 

  15. Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, Sakhuja V, Jha V: The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005; 20: 2720–2724.

    Article  PubMed  Google Scholar 

  16. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM: A meta-analysis of the effect of Bacille-Calmette-Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804–809.

    Article  PubMed  CAS  Google Scholar 

  17. Pai M, Riley LW, Colford JMJr: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761–776.

    Article  PubMed  CAS  Google Scholar 

  18. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340–354.

    PubMed  Google Scholar 

  19. Mazurek GH, Villarino ME: Guidelines for using the Quanti-FERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 15–18.

    PubMed  Google Scholar 

  20. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV: Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737–742.

    Article  PubMed  Google Scholar 

  21. Kunimoto D, Birse T, Lindemulder A, Manning T, Miedzinski L, Saxinger L, Shafran S, Taylor G, Houston S. QuantiFERON-TB Gold testing of HIV patients for latent TB infection. Can J infect Dis Med Microbiol 2006; 17.

  22. Rangaka MX, Wilkinson KA, Seldon R, Van Cutsem G, Meintjes GA, Morroni C, Mouton P, Diwakar L, Connell TG, Maartens G, Wilkinson RJ: Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514–520.

    Article  PubMed  Google Scholar 

  23. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P: Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7: 56.

    Article  PubMed  Google Scholar 

  24. Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M: Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007; 2: 68–73.

    Article  PubMed  Google Scholar 

  25. Cellestis Ltd.: QuantiFERON®-TB Gold Analysis Software. Available at: http://www.cellestis.com/IRM/content/aust/SoftwareDownloadAU.aspx. Accessed 24 July 2007.

  26. CDC-Taiwan: Taiwan guideline on TB diagnosis and treatment. In: CDC-Taiwan (eds): 2nd edn. Taiwan Centers for Disease Control, Taipei 2006.

    Google Scholar 

  27. Landis JR, Koch GG: An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977; 33: 363–374.

    Article  PubMed  CAS  Google Scholar 

  28. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH: Tuberculosis in patients with end-stage renal disease. Am J Med 1980; 68: 59–65.

    Article  PubMed  CAS  Google Scholar 

  29. Korzets A, Gafter U: Tuberculosis prophylaxis for the chronically dialysed patient-yes or no? Nephrol Dial Transplant 1999; 14: 2857–2859.

    Article  PubMed  CAS  Google Scholar 

  30. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A: Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164–1170.

    Article  PubMed  Google Scholar 

  31. Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T, Sybrecht GW, Lalvani A, Kohler H: Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 2004; 65: 1826–1834.

    Article  PubMed  Google Scholar 

  32. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W: Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol 2006; 44: 2844–2850.

    Article  PubMed  CAS  Google Scholar 

  33. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, Mussini C, Rumpianesi F, Fabbri LM, Richeldi L: Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328–1334.

    Article  PubMed  CAS  Google Scholar 

  34. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D’Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L: Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631–635.

    Article  PubMed  Google Scholar 

  35. Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T: Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006; 7: 77.

    Article  PubMed  CAS  Google Scholar 

  36. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ: Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756–2761.

    Article  PubMed  CAS  Google Scholar 

  37. Mahomed H, Hughes EJ, Hawkridge T, Minnies D, Simon E, Little F, Hanekom WA, Geiter L, Hussey GD: Comparison of Mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Int J Tuberc Lung Dis 2006; 10: 310–316.

    PubMed  CAS  Google Scholar 

  38. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T: Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol 2006; 27: 442–448.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Y. C. Liu.

Additional information

The results of this study have been previously reported in part, in the form of an abstract, at the 46th Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27–30 September, 2006. San Francisco, USA. Abstract D460: S.S. Lee, Y.Y. Ni, T.S. Huang, K.R. Chou, H.C. Fang, H.C. Tsai, Y.S. Chen, S.R. Wann, H.H. Lin, Y.C. Liu. QuantiFERON-TB GOLD for Diagnosis of Latent Tuberculosis Infection in Patients with End-Stage Renal Disease in Taiwan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, S.S.J., Chou, K.J., Su, I. et al. High Prevalence of Latent Tuberculosis Infection in Patients in End-Stage Renal Disease on Hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and Tuberculin Skin Test. Infection 37, 96–102 (2009). https://doi.org/10.1007/s15010-008-8082-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-008-8082-3

Keywords

Navigation